Shana Wingo, MD, discusses the surgical landscape in patients with newly diagnosed ovarian cancer.
Dennis R. Scribner Jr, MD, discusses the elements and evolution of treatment for patients with recurrent ovarian cancer.
Mike Janicek, MD, discusses the importance of genetic testing and how the ovarian field can benefit from a better understanding of it through genetic counselors and self-education.
Matthew Borst, MD, highlights the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.
Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.
Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.
The European Commission has approved olaparib tablets (Lynparza) as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer.
Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.
Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.
Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.